stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.95
0.78
+6.41%
Follow KLRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | 0 | (149) | (348) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | 0 | (149) | (348) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | (949.00) | 85,600,598.17 | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | 0.00 | (765.67) | (2.51) | n/m | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (13.30) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | 0.00 | (778.97) | (2.51) | n/m | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.00 | 4,050.36 | 7.95 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | 0 | 58 | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | 0 | (120) | (326) | n/m | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | (2) | — | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | 0 | (122) | (326) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 171 | 511 | 878 | +199.4% | |||||
| Net debt | — | — | — | — | — | — | — | — | (175) | (546) | (901) | +211.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 172 | 636 | 1,031 | +270.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | (34.21) | (55.25) | — | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (110.14) | (182.92) | (110.1) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | — | 51.79 | (85.74) | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 145 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 6 Nov 2026
Kailera Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics, Inc. | $1.6B | 6.1× | 5.5× | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| ABSI Absci Corporation | $1.6B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| GENB Generate Biomedicines, Inc. | $1.6B | — (loss-making) | — (loss-making) | — | n/m | −224.24% (below 0%: shrinking) | 100.00% | (1,134.21%) | Compare |
| NVAX Novavax, Inc. | $1.6B | — (loss-making) | 110× | −3.05% (below 0%: shrinking) | n/m | −189.09% (below 0%: shrinking) | 65.61% | (45.80%) | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $1.6B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KLRA Kailera Therapeutics, Inc. | $1.6B | — (loss-making) | — | — | n/m | −325.95% (below 0%: shrinking) | — | 0.00% | |
| BRVE Braveheart Bio, Inc. | $1.6B | — | — | — | n/m | — | — | 0.00% | Compare |
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −48.03% (below 0%: shrinking) | n/m | −11.05% (below 0%: shrinking) | 100.00% | (1,707.73%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +8.13% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 81.50% | (63.58%) | Compare |
| Median of peers | $1.6B | — | — | −24.71% | — | −11.05% | 100.00% | (54.69%) |